Brain and Nervous System, Phase III

A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Amy L. Rodrigues

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Sylvia Kurz, MD, PhD
Associate Professor of Neurology; Associate Professor of Neurology, Neuro-Oncology; Co-Director, Chênevert Family Brain Tumor Center

Sub-Investigators

Last Updated
03/08/2026
Study IRB
#2000041382